173 filings
Page 4 of 9
8-K
4p4tnnuote5cbtf
24 Aug 21
Timber Pharmaceuticals Announces Last Patient Last Visit in Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis
8:21am
8-K
m6jfffck0glqu
10 Aug 21
Timber Pharmaceuticals Provides Business Update and Announces Second Quarter 2021 Financial Results
12:09pm
8-K
xc4e5cx1g8o43ss 1tt
2 Jul 21
Submission of Matters to a Vote of Security Holders
4:08pm
8-K
gr5m5 bgv4w2psm0
1 Jul 21
Regulation FD Disclosure
8:27am
8-K
btdijbetqr
3 Jun 21
Timber Pharmaceuticals Announces Adjournment
4:14pm
8-K
ua9lud4yaz5644r
26 May 21
Timber Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2b CONTROL Study Evaluating TMB-001 in Congenital Ichthyosis
5:19pm
8-K
1dq6fzjsy0fws5
11 May 21
Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2021 Financial Results
4:53pm
8-K
ol7 sm2rsxh9pr
28 Apr 21
Timber Pharmaceuticals Receives Decision to Grant Japanese Patent for Lead Asset TMB-001
8:20am
8-K
is0 1mb1vibqk
23 Apr 21
Timber Pharmaceuticals Announces Appointment of John Koconis as Chairman of the Board of Directors
8:21am
8-K
s0cvyl
16 Apr 21
Departure of Directors or Certain Officers
4:22pm
8-K
x7bnl5idc 6h
23 Mar 21
Timber Pharmaceuticals Provides Business Update and Announces Year End 2020 Financial Results
4:12pm
8-K
x5w k87xj793gt77
17 Mar 21
Timber Pharmaceuticals’ Development Partner, AFT Pharmaceuticals, Enters into Licensing Agreement for Pascomer® (TMB-002) in Europe
8:19am
8-K
b780bm9w8 05
16 Mar 21
Entry into a Material Definitive Agreement
4:38pm
8-K
38rpc2uzolr bnon
4 Feb 21
Regulation FD Disclosure
4:06pm
8-K
a1074avmdbgyegi
25 Jan 21
Timber Pharmaceuticals Appoints Alan Mendelsohn, M.D., as Chief Medical Officer
4:11pm
8-K
qai1 l2vaauke71u3m
12 Jan 21
Timber Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for TMB-003 for the Treatment of Systemic Sclerosis
9:38pm
8-K
0xc09 6c7osqbi72
17 Dec 20
Regulation FD Disclosure
9:00am
8-K
5gsvpin 9pevm8z7id7
20 Nov 20
Entry into a Material Definitive Agreement
9:00am
8-K
ig7xepa1tcii8 0ruo
12 Nov 20
Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2020 Financial Results
5:07pm
8-K
cpgzv2yq ufw
16 Sep 20
Regulation FD Disclosure
12:11pm